A Phase 2 interventional study of VX-745 in Alzheimer's Disease and Mild Cognitive Impairment, sponsored by EIP Pharma Inc. Completed at 1 site in Netherlands. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-14.
Sponsored by EIP Pharma Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Alzheimer Disease with a site in Netherlands — 17 open to participants now, 28 under way, 10 of them phase 3. Alzheimer Disease · Netherlands.
Among the 134 studies in Alzheimer Disease with a site in Netherlands, this one is the 112th largest by enrollment of the 120 interventional ones that give a count, is one of 10 that started in 2015, is one of 31 in phase 2, and was the 51st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →17 of the 134 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Netherlands, Australia, Austria and 14 more countries
Ages 18+
Denali Therapeutics Inc. · Sites in Netherlands, United Kingdom
Ages 18–75
Alnylam Pharmaceuticals · Sites in Netherlands, Canada, Spain and 1 more country
Ages 40–80
Alzheimercentrum Amsterdam · Sites in Netherlands
Ages 55+
Bristol-Myers Squibb · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 60–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 60 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 46 · Phase 3 48 · Phase 4 1
First in 2000; this study’s year is marked. 10 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 246 across the 120 interventional studies, 502 across the 14 observational. Of the 99 that completed or were terminated, 45 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 134 have an industry lead sponsor. The 10 most frequent:
EIP Pharma Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
EIP Pharma Inc has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Alzheimer Disease with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891716AC Immune SA[18F]ACI-19626 PET in TDP-43 Proteinopathies | 2026-11 |
| NCT07680335Alzheimercentrum AmsterdamThe BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07328451Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | 2027-02 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 134 studies in Alzheimer Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD). Subjects who meet entry criteria will undergo 11C-PiB (Carbon-11-labeled Pittsburgh Compound B) positron emission tomography (PET) at baseline and after 45 days of dosing with VX-745. Cognitive testing will also be conducted at baseline and day 45.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Group 1: VX-745 40 mg twice daily
Drug: VX-745
Active Group 2: VX-745 125 mg twice daily
Drug: VX-745
Orally-Active Selective P45 MAP Kinase inhibitor
Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET
Percent change in global cortical amyloid specific PET signal (BPND)
Time frame: Baseline compared to following 12 weeks' dosing with VX-745
Number of 11C-PiB Responders
Number of patients meeting protocol pre-specified definition of response: \> 7% reduction in global cortical BPND
Time frame: Day 84
Wechsler Memory Scale (WMS) Immediate Recall Composite
WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.
Time frame: Baseline to Day 84
Wechsler Memory Scale (WMS) Delayed Recall Composite
WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.
Time frame: Change from baseline to Day 84
| Milestone | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 |
|---|---|---|
| Started | 9 | 7 |
| Completed | 9 | 7 |
| Not completed | 0 | 0 |
Percent change in global cortical amyloid specific PET signal (BPND)
| percentage change from baseline | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 |
|---|---|---|
| Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET | -4.57 (-11.65 to 4.83) | 4.57 (0.56 to 12.25) |
Number of patients meeting protocol pre-specified definition of response: \> 7% reduction in global cortical BPND
| Participants | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 |
|---|---|---|
| Number of 11C-PiB Responders | 3 | 1 |
WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.
| units on a scale | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 |
|---|---|---|
| Wechsler Memory Scale (WMS) Immediate Recall Composite | 7.0 ± 11.0 | 13.4 ± 12.2 |
WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.
| units on a scale | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 |
|---|---|---|
| Wechsler Memory Scale (WMS) Delayed Recall Composite | 7.5 ± 7.0 | 10.4 ± 11.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 40 mg Dose Group | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| 125 mg Dose Group | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | 40 mg Dose Group | 125 mg Dose Group |
|---|---|---|
| DiarrheaGastrointestinal disorders | 3/9 | 0/7 |
| SomnolenceNervous system disorders | 1/9 | 1/7 |
| Abdominal painGastrointestinal disorders | 1/9 | 1/7 |
| Influenza like illnessGeneral disorders | 1/9 | 1/7 |
| Age, Continuous(years) | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 | Total |
|---|---|---|---|
| Median | 68 (60 to 76) | 65 (60 to 75) | 66.5 (60 to 76) |
| Sex: Female, Male(Participants) | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 7 | 3 | 10 |
| Region of Enrollment(participants) | Neflamapimod (VX-745) Dose 1 | Neflamapimod (VX-745) Dose 2 | Total |
|---|---|---|---|
| Netherlands | 9 | 7 | 16 |
The record gives a start of Apr 2015, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VX-745
EIP Pharma Inc